EUROPEAN COMMISSION

Brussels, 25.10.2022
C(2022) 7832 final

PUBLIC VERSION

QuattroR SGR S.p.A.
Via Borgonuovo 14
20121 Milan
Italy

International Medical Technology Collective S.C.A.
Rue Aldringen 11
L-1118 Luxembourg
Luxembourg

Subject: **Case M.10893 – QUATTROR / IMTC / MTD**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

Dear Sir or Madam,

1. On 3 October 2022, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which QuattroR SGR S.p.A. ('QuattroR', Italy), and International Medical Technology Collective S.C.A. ('IMTC', Luxembourg), controlled by Investindustrial S.A. ('Investindustrial', Luxembourg), will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control over the whole of Medical Technology and Devices SA ('MTD', Switzerland) by way of purchase of shares.[3]

2. The business activities of the undertakings concerned are the following:

   – QuattroR manages an Italian private equity fund and currently controls five portfolio companies in the area of engineering, logistics and manufacturing,

---

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union No C 388, 10.10.2022, p. 9.

– IMTC is an investment subsidiary of Investindustrial, an investment group focusing on consumer and leisure, healthcare and services, industrial manufacturing and technology,

– MTD, a Swiss-based med-tech group that designs, develops, and provides medical devices globally, particularly diabetes management devices, standard and safety sharp devices, electro-medical devices and wound-care products.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(b) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.[4]

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

4 OJ C 366, 14.12.2013, p. 5.